Influence of Resveratrol Supplementation on Pregnancy Outcomes in in vitro Fertilization–Embryo Transfer Cycles

Abstract Research question Does a polyphenolic compound, resveratrol affect pregnancy outcomes following in vitro fertilization and embryo transfer? Design This single-center, cross-sectional retrospective study was designed to compare the outcomes of ET cycles between women receiving resveratrol supplementation (200 mg/d) continuously (RES group) and a control group (non-RES group). Of 8,686 ET cycles, we excluded 1,409 cycles with poor prognostic factors, including those women aged over 43 years and those with morphologically poor-quality embryos. The RES group (204 cycles, 102 women) was then compared with the non-RES group (7,073 cycles, 2,958 women). Results After matching patients by patient age at the time of oocyte retrieval, grade and development stage of embryos, number of embryos transferred, and fresh or frozen-thawed embryo transfer as confounding factors, multivariate logistic regression analysis showed that resveratrol intake is strongly associated with a decrease in clinical pregnancy rate (odds ratio: 0.539; 95% confidence intervals: 0.341–0.853) and an increased risk of miscarriage (odds ratio: 2.602; 95% confidence intervals: 1.070–6.325). Conclusions Resveratrol supplementation during embryo transfer cycles appears to be detrimental for pregnancy outcomes. To be clinically useful, an analysis of the supplementation protocol and randomized controlled study are needed.